Intellectual Property

Pharmaceutical companies encounter major Intellectual Property (IP) challenges when   bringing new products to market in addition to facing post-commercialization issues requiring attention in order to mitigate financial and legal exposure.

Operating within a global landscape presents a myriad of associated benefits and risks, against a backdrop of statutory obligations (sector specific & financial) which are required to be met. It is in adhering to these legal requirements that CiPharma’s local knowledge, historical perspective and expertise in key emerging markets becomes of paramount value.

It’s origins in North America combined with experience and reach compassing Europe, the Middle-east and Africa (EMEA) allows your organization to draw on a network of local investigators, researchers and legal practitioners with knowledge spanning both core and emerging economies ensuring product integrity and protection of IP rights.